ArticleClinical and translational medicine2021
Multi-omics consensus ensemble refines the classification of muscle-invasive bladder cancer with stratified prognosis, tumour microenvironment and distinct sensitivity to frontline therapies.
Open access · goldAbstract readLetter
In one paragraph
Article in Clinical and translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
9.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 65 citations in OpenAlex.
- A cross-scale multimodal framework identifies clinically actionable immunotherapy biomarkers in melanoma through bulk to single-cell and spatial transcriptomics integration.Human genomics · 2026Article
- EMC3 as a Novel Biomarker and Driver of PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma Progression.Annals of surgical oncology · 2026Article
- The GFPT2/O-GlcNAcylation/c-Myc axis promotes bladder cancer progression.Journal of translational medicine · 2026Article
- Predicting neuroblastoma prognosis using machine learning analysis of metabolism-related gene network perturbation.BMC pediatrics · 2026Article
- CDCSI: a machine learning-based interpretable cell death and cellular senescence index for prognosis improvement, immune landscape characterization, and therapeutic response prediction in head and neck squamous cell carcinoma.Frontiers in immunology · 2026Article
- Molecular subtyping and prognostic modeling of colon adenocarcinoma based on programmed cell death features: a multi-omics and machine learning study.Frontiers in immunology · 2026Article
- Comprehensive omics-based classification system in adult patients with B-cell acute lymphoblastic leukemia.Molecular oncology · 2025Article
- Advancing prognostic and therapeutic prediction in lung squamous cell carcinoma through integrated multi-omics analysis and 117 machine learning combinations.Journal of thoracic disease · 2025Article
- Integrative multiomics analysis reveals the subtypes and key mechanisms of platinum resistance in gastric cancer: identification of KLF9 as a promising therapeutic target.Journal of translational medicine · 2025Article
- Integrated multi-omics analysis and machine learning refine molecular subtypes and prognosis in hepatocellular carcinoma through O-linked glycosylation genes.Functional & integrative genomics · 2025Article
- Comprehensive multi-omics and machine learning framework for glioma subtyping and precision therapeutics.Scientific reports · 2025Article
- Integrated multiomics analysis and machine learning refine molecular subtypes and prognosis for thyroid cancer.Discover oncology · 2025Article
- Classification of acute myeloid leukemia based on multi-omics and prognosis prediction value.Molecular oncology · 2025Article
- Article
- Tumor microenvironment and drug resistance in lung adenocarcinoma: molecular mechanisms, prognostic implications, and therapeutic strategies.Discover oncology · 2025Article
- Machine learning model reveals the risk, prognosis, and drug response of histamine-related signatures in pancreatic cancer.Discover oncology · 2025Article
- Improving molecular subtypes and prognosis of pancreatic cancer through multi group analysis and machine learning.Discover oncology · 2025Article
- Integrating Spatial Multi-Omics and Machine Learning to Unravel the Role of PANoptosis in Bladder Cancer Prognosis and Immunotherapy Response.Oncology research · 2025Article
- Identification and characterization of senescent macrophages in renal allograft rejection: a cross-species MultiOmics study.Frontiers in immunology · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 3 countries.
Xiaofan LuState Key Laboratory of Natural Medicines, Research Center of Biostatistics and Computational Pharmacy, China Pharmaceutical University, Nanjing, P.R. China.ORCID 0000-0003-2417-6548
Jialin MengDepartment of Urology, The First Affiliated Hospital of Anhui Medical University, Institute of Urology, Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical University, Hefei, Anhui, P.R. China.ORCID 0000-0002-4622-833X
Liwen SuState Key Laboratory of Natural Medicines, Research Center of Biostatistics and Computational Pharmacy, China Pharmaceutical University, Nanjing, P.R. China.
Liyun JiangState Key Laboratory of Natural Medicines, Research Center of Biostatistics and Computational Pharmacy, China Pharmaceutical University, Nanjing, P.R. China.
Haitao WangCancer Center, Faculty of Health Sciences, Center for Precision Medicine Research and Training, University of Macau, Macau, P.R. China.
Junkai ZhuState Key Laboratory of Natural Medicines, Research Center of Biostatistics and Computational Pharmacy, China Pharmaceutical University, Nanjing, P.R. China.
Mengjia HuangState Key Laboratory of Natural Medicines, Research Center of Biostatistics and Computational Pharmacy, China Pharmaceutical University, Nanjing, P.R. China.
Wenxuan ChengState Key Laboratory of Natural Medicines, Research Center of Biostatistics and Computational Pharmacy, China Pharmaceutical University, Nanjing, P.R. China.
Li XuState Key Laboratory of Natural Medicines, Research Center of Biostatistics and Computational Pharmacy, China Pharmaceutical University, Nanjing, P.R. China.
Xinjia RuanState Key Laboratory of Natural Medicines, Research Center of Biostatistics and Computational Pharmacy, China Pharmaceutical University, Nanjing, P.R. China.
Shuyuan YehGeorge Whipple Lab for Cancer Research, Departments of Pathology, Urology, Radiation Oncology, and The Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, USA.
Chaozhao LiangDepartment of Urology, The First Affiliated Hospital of Anhui Medical University, Institute of Urology, Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical University, Hefei, Anhui, P.R. China.
Fangrong YanState Key Laboratory of Natural Medicines, Research Center of Biostatistics and Computational Pharmacy, China Pharmaceutical University, Nanjing, P.R. China.ORCID 0000-0003-3347-5021
China Pharmaceutical University · CNAnhui Medical University · CNThe University of Texas MD Anderson Cancer Center · USUniversity of Macau · MOUniversity of Rochester Medical Center · US
Funding
Active Components of Natural Medicines and Independent Research Projects of the State Key Laboratory SKLNMZZ202016Key R&D Program of Jiangsu Province BE2020694National Key R&D Program of China 2019YFC1711000National Natural Science Foundation of China 81630019National Natural Science Foundation of China 81870519National Natural Science Foundation of China 81973145Supporting Project for Distinguished Young Scholar of Anhui Colleges gxyqZD2019018
Abstract
PubMed holds no abstract for this paper.
Indexed as
PrognosisTumor MicroenvironmentUrinary Bladder NeoplasmsBiomarkers, TumorConsensus SequenceHumansBiomarkers, Tumor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.